2 results about "Melanocortins" patented technology

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

The present application relates to the technical field of bioactive peptides, and in particular to an oat oligopeptide, preparation thereof and application thereof in preparing a product for regulating the expression of brain appetite suppressor factor. The oat oligopeptide can effectively stimulate the release of cholecystokinin (CCK) from intestinal endocrine cells, and stimulate the central nervous system through the vagus nerve pathway, thereby promoting the expression of the appetite suppressor factor pro-opiomelanocortin (POMC) in the hypothalamus. Compared with the prior art, the oat oligopeptide has the advantages of stable structure, high safety, simple preparation process (conventional enzymatic hydrolysis and chromatographic purification can achieve the preparation), easy scale production and the like. The oat oligopeptide is suitable for being used as a functional ingredient or a drug precursor to develop a related health product with the functions of regulating appetite and promoting satiety, and has a wide application prospect in the field of preparing functional products (food, medicine and the like).